Drug Profile
TLD 1433
Alternative Names: PDT; Ruvidar; TLD-1433Latest Information Update: 16 Jan 2024
Price :
$50
*
At a glance
- Originator Theralase Technologies
- Developer Theralase Technologies; University Health Network
- Class Antineoplastics
- Mechanism of Action Photosensitisers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Bladder cancer
Most Recent Events
- 15 Jan 2024 Theralase Technologies announces intention to re-submit pre-Break Through Designation to US FDA
- 15 Jan 2024 Theralase Technologies anticipates regulatory approvals with Health Canada and FDA approval by 2026/2027
- 15 Jan 2024 Efficacy and adverse events data from a phase II trial Bladder cancer released by Theralase Technologies